Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotechRead More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 20 February 2018SV NewsDDF welcomes recent FDA guidance which opens new paths for Alzheimer’s treatments
- 1 February 2018Portfolio NewsAVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases
- 31 January 2018Portfolio NewsBill Gates interview cites DDF investment
- 16 January 2018Portfolio NewsNordic Acquires The Claro Group’s Revenue Cycle Transformation Practice
- 16 January 2018SV NewsSV Health Investors Announces Promotions Within Financial Team
- 8 January 2018SV NewsSV Health Investors Promotes Michael Balmuth to Managing Partner and Houman Ashrafian to Partner
- 2 January 2018SV NewsJLABS - Meet With...Dementia Discovery Fund
- 13 December 2017Portfolio NewsPionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment
- 16 November 2017SV NewsDDF attracts investment from NFL Players Association
- 3 November 2017Portfolio NewsDDF attracts $50 million investment from Bill Gates
- 24 October 2017Portfolio NewsDDF notes major collaboration between portfolio company Alector and AbbVie
- 6 July 2017Portfolio NewsDDF Invests in $20 Million in Series A Funding of Mitoconix Bio to Develop Neurodegenerative Disease Therapies